Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara F., D'Rozario, James, Owen, Carolyn J., Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz ORCID: 0000-0002-3411-6357, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Panchal, Anesh, Lu, Tong, Wu, Jenny Q., Jiang, Yanwen, Lefebure, Marcus, Boyer, Michelle and Kater, Arnon P. (2022). Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, 140 (8). S. 839 - 851. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and overall survival (OS) with venetoclax-rituximab (VenR) vs bendamustine-rituximab (BR) in relapsed/refractory (R/R) CLL. Patients were randomized to 2 years of VenR (n = 194; rituximab for the first 6 months) or 6 months of BR (n = 195). Although undetectable minimal residual disease (uMRD) was achieved more often with VenR, the long-term implications of uMRD with this fixed-duration, chemotherapy-free regimen have not been explored. We report MRD kinetics and updated outcomes with 5 years' follow-up. Survival benefits with VenR vs BR were sustained (median PFS [95% confidence interval]: 53.6 [48.4, 57.0] vs 17.0 [15.5, 21.7] months, respectively, P < .0001; 5-year OS [95% confidence interval]: 82.1% [76.4, 87.8] vs 62.2% [54.8, 69.6], P < .0001). VenR was superior to BR, regardless of cytogenetic category. VenR-treated patients with uMRD at end of treatment (EOT; n = 83) had superior OS vs those with high-MRD+ (n = 12): 3-year post-EOT survival rates were 95.3% vs 72.9% (P = .039). In those with uMRD at EOT, median time to MRD conversion was 19.4 months. Of 47 patients with documented MRD conversion, 19 developed progressive disease (PD); median time from conversion to PD was 25.2 months. A population-based logistic growth model indicated slower MRD median doubling time post-EOT with VenR (93 days) vs BR (53 days; P = 1.2 x 10(-7)). No new safety signals were identified. Sustained survival, uMRD benefits, and durable responses support 2-year fixed-duration VenR treatment in R/R CLL.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Seymour, John F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kipps, Thomas J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eichhorst, Barbara F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
D'Rozario, JamesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Owen, Carolyn J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Assouline, SaritUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lamanna, NicoleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Robak, TadeuszUNSPECIFIEDorcid.org/0000-0002-3411-6357UNSPECIFIED
de la Serna, JavierUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jaeger, UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cartron, GuillaumeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Montillo, MarcoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mellink, ClemensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chyla, BrendaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Panchal, AneshUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lu, TongUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wu, Jenny Q.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jiang, YanwenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lefebure, MarcusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boyer, MichelleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kater, Arnon P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-695717
DOI: 10.1182/blood.2021015014
Journal or Publication Title: Blood
Volume: 140
Number: 8
Page Range: S. 839 - 851
Date: 2022
Publisher: AMER SOC HEMATOLOGY
Place of Publication: WASHINGTON
ISSN: 1528-0020
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CHRONIC LYMPHOCYTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; OPEN-LABEL; INDEPENDENT PREDICTOR; 17P DELETION; SURVIVAL; CYCLOPHOSPHAMIDE; FLUDARABINE; CANCER; QUANTIFICATIONMultiple languages
HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69571

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item